|
Dr. Lampidis trained in radiation biology at the Harvard School of Public Health and in oncology at the Harvard Dana Farber Cancer Institute. His expertise lies in the mechanisms involved in cancer drug resistance and how drugs affect different components of cell metabolism and function. His background in cancer drug pharmacology has lead him to his most recent contributions on targeting the slow growing population of tumor cells with glycolytic inhibitors which is soon to be tested in human trials. He has organized international meetings on drug resistance, served as reviewer on NIH study sections, received numerous NIH Awards, has been an invited speaker internationally and has won awards for excellence in teaching. His work has been published in Science, PNAS and other prestigious journals. | 